Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 0.58 |
| ▸ | EYA3 | Q99504 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30753455 | 0.82 | CYP2C19 (0.54) | CYP2C19EYA3CYP2C9ALDH1A1KDM4E | |
| SCHEMBL30753472 | 0.82 | CYP2C19 (0.54) | CYP2C19EYA3CYP2C9KDM4ENPC1 | |
| SCHEMBL9657351 | 0.80 | CYP2C19 (0.63) | CYP2C19EYA3CYP2C9NPC1RAB9A | |
| SCHEMBL1398779 | 0.80 | CYP2C19 (0.63) | CYP2C19EYA3CYP2C9ALDH1A1KDM4E | |
| SCHEMBL18018241 | 0.79 | CYP2C19 (0.61) | CYP2C19EYA3CYP2C9ALDH1A1KDM4E | |
| SCHEMBL5241666 | 0.79 | GAA (0.52) | CYP2C19EYA3CYP2C9ALDH1A1KDM4E | |
| SCHEMBL26335570 | 0.79 | CA12 (0.56) | CYP2C19CYP2C9ALDH1A1KDM4EHPGD | |
| SCHEMBL944525 | 0.79 | GAA (0.52) | CYP2C19EYA3CYP2C9ALDH1A1KDM4E | |
| SCHEMBL4670295 | 0.79 | CYP2C19 (0.61) | CYP2C19EYA3CYP2C9ALDH1A1KDM4E | |
| SCHEMBL20441188 | 0.79 | CYP2C19 (0.61) | CYP2C19EYA3CYP2C9KDM4ETHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | claimed |
| CN-117285518-A | Quinazoline derivative containing benzofuran structure and application thereof | 华侨大学 | 2023-12-26 | — | — | CN | claimed |
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| CN-120051468-A | Hydrate of VEGFR inhibitor, crystal form thereof and preparation method thereof | 成都苑东生物制药股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-120051468-A | Hydrate of VEGFR inhibitor, crystal form thereof and preparation method thereof | 成都苑东生物制药股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-120025319-A | New crystal form of quinazoline compound | 南京正大天晴制药有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-120025320-A | Quinazoline hydrate of compound | 南京正大天晴制药有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-117285518-A | Quinazoline derivative containing benzofuran structure and application thereof | 华侨大学 | 2023-12-26 | — | — | CN | disclosed |
| CN-115003332-A | Application of anti-PD-1 antibody and furoquintinib combination in preparation of medicine for treating cancer | 嘉和生物药业有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-113200966-B | Furosetinib derivative, pharmaceutical composition and application | 深圳大学 | 2022-07-22 | — | — | CN | disclosed |
| WO-2010025138-A2 | PYRIMIDINE COMPOUNDS | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | FLT1, KDR, FLT4 | CYP2C19 166/4885EYA3 3188/4885CYP2C9 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.